How to Get Belsomra (Suvorexant) in Wisconsin

What Is Suvorexant and Why Consider It for Insomnia?

Suvorexant is the first FDA-approved dual orexin receptor antagonist, a class of sleep medications that works by blocking wake-promoting orexin neuropeptides rather than broadly sedating the central nervous system. The FDA approved Belsomra in 2014 at doses of 5 mg, 10 mg, 15 mg, and 20 mg for adults with insomnia.

The distinction between suvorexant and older sedative-hypnotics matters clinically. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) act on GABA receptors and carry well-documented risks of dependence, complex sleep behaviors, and rebound insomnia on discontinuation. Suvorexant's mechanism targets the orexin system selectively. In the key phase 3 trial by Herring et al. (Lancet Neurology, 2014; N=3,291), suvorexant 40 mg and 20 mg significantly improved both subjective total sleep time (sTST) and wake after sleep onset (sWASO) over 3 months compared with placebo [1]. The 20 mg dose increased sTST by approximately 20 to 25 minutes versus placebo at month 1, and the effect was sustained through month 3. That trial also demonstrated next-day residual effects at higher doses, which led the FDA to recommend a starting dose of 10 mg.

For Wisconsin patients who have tried and failed first-line behavioral approaches like cognitive behavioral therapy for insomnia (CBT-I) or who cannot tolerate Z-drugs, suvorexant represents a mechanistically distinct alternative. The American Academy of Sleep Medicine's 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults [2].

Wisconsin Telehealth Prescribing Rules for Belsomra

Wisconsin law permits telehealth prescribing of Schedule IV controlled substances, including suvorexant, without requiring an in-person visit first. This makes Belsomra accessible to residents across every Wisconsin county, from Milwaukee and Madison to rural areas in the Northwoods.

A telehealth prescriber must hold an active Wisconsin medical license (or a multistate license with Wisconsin privilege under the Interstate Medical Licensure Compact). The prescriber also needs a valid DEA registration. Wisconsin Administrative Code Med 24 governs telehealth encounters and requires that the provider establish a legitimate provider-patient relationship during the visit. That relationship can be formed entirely through a synchronous audio-video encounter. No prior in-person evaluation is necessary for Schedule IV substances.

During a telehealth visit for Belsomra, expect the provider to screen for contraindications: narcolepsy (suvorexant could worsen cataplexy), severe hepatic impairment, and concurrent use of strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin. The Belsomra prescribing information lists concomitant strong CYP3A4 inhibitor use as a contraindication because these drugs can increase suvorexant exposure several-fold [3]. Providers should also evaluate for obstructive sleep apnea, depression, and substance use history before issuing a prescription.

Who Can Prescribe Belsomra in Wisconsin?

Any clinician with prescriptive authority and a DEA registration can prescribe suvorexant in Wisconsin. That includes physicians (MD and DO), nurse practitioners, and physician assistants.

Wisconsin nurse practitioners operate under a collaborative agreement for the first 3,500 hours of clinical practice after licensure. After that threshold, NPs gain full practice authority under Wisconsin Statute 441.16, allowing independent prescribing of controlled substances through Schedule II (and by extension, Schedule IV medications like suvorexant). Physician assistants in Wisconsin prescribe under a collaborative agreement with a supervising physician, per Wisconsin Statute 448.9726, and may prescribe Schedule II through V controlled substances.

Practically, this means patients in smaller Wisconsin communities can see an NP or PA at a local clinic or through a telehealth platform without needing a referral to a sleep specialist. Sleep medicine specialists are concentrated in urban centers (UW Health in Madison, Froedtert and Medical College of Wisconsin in Milwaukee, Marshfield Clinic Health System), but the prescribing scope for suvorexant does not require board certification in sleep medicine.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service Medicaid) covers Belsomra with prior authorization. The PA process exists because suvorexant is a branded, non-preferred agent on the Wisconsin Medicaid Preferred Drug List.

Prior authorization typically requires documentation of the following:

1. A diagnosis of insomnia disorder (ICD-10 codes G47.00 or F51.01)
2. Evidence that the patient has tried or has a contraindication to at least one preferred formulary sleep agent (commonly generic zolpidem or generic trazodone)
3. Clinical rationale for why suvorexant is medically necessary (e.g., prior adverse reaction to Z-drugs, history of substance use disorder making GABA-ergic agents higher risk, or failure of CBT-I)
4. Prescriber's NPI and DEA number

The PA request goes through Wisconsin's Medicaid fiscal agent. Processing time averages 24 to 72 hours for standard requests. Urgent requests (defined as situations where waiting could seriously jeopardize the patient's health) must be adjudicated within 24 hours per federal Medicaid rules (42 CFR § 438.210).

For patients enrolled in Wisconsin Medicaid managed care organizations (MCOs) such as Quartz, Molina, or Dean Health Plan, the PA process routes through the specific MCO. Each MCO maintains its own formulary, though all must provide access to Belsomra if the PA criteria are met. A 2020 analysis published in JAMA Network Open found that prior authorization requirements for branded insomnia medications varied significantly across state Medicaid programs but did not consistently reduce inappropriate prescribing [4].

Commercial Insurance and Manufacturer Savings

Commercial insurers in Wisconsin generally place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays of $40 to $75 for a 30-day supply. Some plans require step therapy through generic zolpidem or generic suvorexant (which became available after Merck's patent exclusivity period).

Merck offers a savings card for commercially insured patients that may reduce the copay to as low as $0 for eligible individuals, with a maximum annual benefit. Patients enrolled in any government-funded program (Medicare Part D, Medicaid, Tricare, VA) are not eligible for the manufacturer savings card under federal anti-kickback regulations.

For uninsured Wisconsin residents, the retail cash price for Belsomra ranges from approximately $350 to $480 for a 30-tablet supply, depending on the pharmacy. Generic suvorexant, where available, may cost $30 to $90 with a discount card through pharmacy benefit aggregators.

503A Compounding Pharmacies in Wisconsin

Wisconsin's Pharmacy Examining Board licenses 503A compounding pharmacies under Wisconsin Statute 450. These pharmacies can compound suvorexant into alternative formulations (e.g., oral suspensions for patients who cannot swallow tablets) based on a valid patient-specific prescription.

Key points about 503A compounding in Wisconsin:

A 503A pharmacy compounds medications pursuant to individual prescriptions, not in bulk for general distribution. The compounded product must be for an identified patient and must differ from the commercially available form in a clinically meaningful way (different strength, dosage form, or the addition of a flavoring agent). Wisconsin 503A pharmacies can ship compounded medications directly to patients within the state.

The prescriber must specify that a compounded formulation is necessary. Insurers rarely cover compounded medications, so patients should expect to pay cash. Typical pricing for a compounded suvorexant suspension runs $60 to $120 for a 30-day supply, depending on the pharmacy and concentration.

Wisconsin-based compounding pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or that have passed state inspection are listed in the Wisconsin Department of Safety and Professional Services pharmacy license lookup database.

What Labs or Tests Are Needed Before Starting Belsomra?

No specific laboratory tests are mandatory before initiating suvorexant. This contrasts with medications like ramelteon (where liver function testing may be considered) or certain off-label insomnia treatments.

Providers should, at minimum, perform a clinical screening that includes:

A thorough sleep history differentiating insomnia from circadian rhythm disorders, restless legs syndrome, or obstructive sleep apnea. The STOP-BANG questionnaire is a validated screening tool for obstructive sleep apnea [5]. If a patient scores 3 or higher, a home sleep apnea test or in-laboratory polysomnography should be completed before prescribing any sedative-hypnotic.

A psychiatric screen. Suvorexant has been associated with worsening depression in some clinical trial participants, though the signal was small. The Herring et al. trial excluded patients with major psychiatric illness, so real-world data on suvorexant in patients with active depression remains limited [1].

A medication reconciliation. Because suvorexant is metabolized by CYP3A4, moderate inhibitors (diltiazem, erythromycin, fluconazole, grapefruit juice in large quantities) warrant dose reduction to 5 mg. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can reduce suvorexant efficacy. The FDA label recommends avoiding concomitant use with strong CYP3A4 inducers [3].

A hepatic function assessment. Suvorexant is contraindicated in severe hepatic impairment (Child-Pugh C). No dose adjustment is needed for mild or moderate hepatic impairment, but a clinician should document liver status in patients with known liver disease.

How Long Until Belsomra Arrives After a Wisconsin Prescription?

From the moment a prescriber sends a suvorexant e-prescription to a Wisconsin pharmacy, the timeline breaks down as follows.

Without prior authorization: if the patient has commercial insurance that covers suvorexant without PA, most retail pharmacies (Walgreens, CVS, Walmart Pharmacy, Pick 'n Save Pharmacy, independent pharmacies) can dispense the medication within 1 to 2 business days. Some pharmacies stock Belsomra routinely; others may need to order it from their wholesaler, adding 24 hours.

With prior authorization: add 1 to 3 business days for the PA adjudication. If the PA is approved, the pharmacy fills the prescription upon notification. If denied, the prescriber can file an appeal, which adds another 5 to 10 business days.

Mail-order pharmacy: many Wisconsin commercial and Medicaid plans allow 90-day mail-order fills. Initial delivery takes 7 to 10 business days; refills ship in 5 to 7 days.

Compounded formulations: 503A pharmacies typically require 3 to 5 business days for compounding and quality checks, plus 1 to 3 days for shipping within Wisconsin.

Total realistic timeline for most Wisconsin patients: 3 to 7 days from telehealth visit to medication in hand.

Transferring a Belsomra Prescription to a Wisconsin Pharmacy

Because suvorexant is a Schedule IV controlled substance, prescription transfers between pharmacies follow DEA regulations under 21 CFR § 1306.26. A Schedule III through V prescription may be transferred between pharmacies one time only, unless the pharmacies share a real-time, online database (as is the case within many chain pharmacy systems like CVS-to-CVS or Walgreens-to-Walgreens).

If a patient moves to Wisconsin from another state, the receiving Wisconsin pharmacy can accept a one-time transfer of the remaining refills. The patient should call the new pharmacy with the original pharmacy's name, phone number, and prescription number. The pharmacist at the receiving pharmacy contacts the originating pharmacy to verify and record the transfer.

Alternatively, a new Wisconsin-based prescriber (in-person or via telehealth) can write a fresh prescription, which is often simpler for patients establishing care in a new state.

Safety Profile and Common Side Effects

The Herring et al. trial and subsequent post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) provide the primary safety profile for suvorexant [1, 3].

The most common adverse events at the 20 mg dose in clinical trials were somnolence (7% vs. 3% placebo), headache (6% vs. 6% placebo), and dizziness (3% vs. 2% placebo). Sleep paralysis occurred in 1% of suvorexant-treated patients versus 0% on placebo. Suicidal ideation was reported rarely and at rates comparable to placebo, though patients with active depression were excluded from the key trials.

A 2022 meta-analysis in the Journal of Clinical Sleep Medicine (N=4,076 across 6 RCTs) found that DORAs as a class had lower rates of next-day psychomotor impairment compared with Z-drugs, though direct head-to-head data remain sparse [6]. Dr. Andrew Krystal, a sleep researcher at UCSF, noted in a 2023 review that "the orexin antagonist mechanism offers a differentiated safety profile, particularly for older adults at risk of falls and cognitive side effects from traditional hypnotics" [7].

The FDA added a boxed warning in 2019 to all orexin receptor antagonists (including suvorexant and lemborexant) regarding complex sleep behaviors (sleepwalking, sleep-driving, engaging in activities while not fully awake). These events are rare but potentially serious.

Suvorexant vs. Other Wisconsin-Available Insomnia Medications

Wisconsin patients and their providers often weigh suvorexant against several alternatives.

Generic zolpidem (5 mg and 10 mg) is the most commonly prescribed insomnia medication in Wisconsin and the default first-step for Medicaid PA. It is inexpensive ($4 to $15 for 30 tablets) but carries higher abuse potential, rebound insomnia risk, and documented complex sleep behaviors. A 2019 study published in JAMA Internal Medicine found that Z-drug use in older adults was associated with a 34% increased risk of hip fracture [8].

Lemborexant (Dayvigo), another DORA, is also available in Wisconsin and works via the same orexin-blocking mechanism as suvorexant. The SUNRISE-2 trial (N=949) showed lemborexant 5 mg and 10 mg maintained efficacy over 12 months for both sleep onset and sleep maintenance [9]. Choice between suvorexant and lemborexant often depends on formulary placement and pricing.

Trazodone (off-label, 25 mg to 100 mg at bedtime) is widely used and inexpensive but lacks strong RCT evidence for insomnia and can cause orthostatic hypotension, priapism, and cardiac arrhythmias at higher doses. A Cochrane review from 2023 concluded that trazodone's evidence base for insomnia remains low-certainty [10].

For Wisconsin patients with both insomnia and depression, dual-purpose agents like doxepin (Silenor, 3 mg and 6 mg) may be appropriate. For those with concurrent pain or fibromyalgia, low-dose gabapentin or pregabalin may address both sleep and pain, though neither is FDA-approved for insomnia.

The prescribing decision should account for the patient's comorbidities, prior medication trials, insurance formulary, and personal preferences around mechanism of action and side effect profile.